QI
VTGN icon

QS Investors’s VistaGen Therapeutics VTGN Stock Holding History

QS Investors’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$561K Buy
+5,930
New +$439K 0.01% 694

Other funds holding VTGN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

QS Investors's VTGN Position: Q2 2021 in Review

QS Investors opened a new position in VistaGen Therapeutics (VTGN) in Q2 2021: 5,930 shares worth $561K. The stake represents 0.01% of the portfolio and ranks #694 among its holdings.

101 funds tracked by Wall St. Rank hold VTGN as of Q2 2021.

  • QS Investors held 5,930 shares of VistaGen Therapeutics worth $561K as of Q2 2021.
  • VistaGen Therapeutics was a new QS Investors position in Q2 2021.
  • VistaGen Therapeutics made up 0.01% of QS Investors's portfolio in Q2 2021, its #694 holding.
  • 101 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2021.

Based on QS Investors's 13F filing for Q2 2021, filed 13 Aug 2021.